Have health trends worsened in Greece as a result of the financial crisis? A quasi-experimental approach S Vandoros, P Hessel, T Leone, M Avendano The European Journal of Public Health 23 (5), 727-731, 2013 | 211 | 2013 |
Reforms in the Greek pharmaceutical market during the financial crisis S Vandoros, T Stargardt Health policy 109 (1), 1-6, 2013 | 147 | 2013 |
Excess mortality during the Covid-19 pandemic: Early evidence from England and Wales S Vandoros Social Science & Medicine 258, 113101, 2020 | 139 | 2020 |
Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs P Kanavos, A Ferrario, S Vandoros, GF Anderson Health affairs 32 (4), 753-761, 2013 | 122 | 2013 |
Differences in costs of and access to pharmaceutical products in the EU P Kanavos, S Vandoros, R Irwin, E Nicod, M Casson EPRS: European Parliamentary Research Service, 2011 | 119 | 2011 |
The association between economic uncertainty and suicide in the short-run S Vandoros, M Avendano, I Kawachi Social Science & Medicine 220, 403-410, 2019 | 100 | 2019 |
Determinants of branded prescription medicine prices in OECD countries PG Kanavos, S Vandoros Health economics, policy and law 6 (3), 337-367, 2011 | 89 | 2011 |
Tender systems for outpatient pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium P Kanavos, L Seeley, S Vandoros LSE Health London School of Economics, 2009 | 83 | 2009 |
The impact of the Great Recession on health-related risk factors, behaviour and outcomes in England M Jofre-Bonet, V Serra-Sastre, S Vandoros Social Science & Medicine 197, 213-225, 2018 | 75 | 2018 |
The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors F Von der Schulenburg, S Vandoros, P Kanavos Health economics review 1, 1-8, 2011 | 71 | 2011 |
The differential impact of the financial crisis on health in Ireland and Greece: a quasi-experimental approach P Hessel, S Vandoros, M Avendano Public health 128 (10), 911-919, 2014 | 58 | 2014 |
The generics paradox revisited: empirical evidence from regulated markets S Vandoros, P Kanavos Applied Economics 45 (22), 3230-3239, 2013 | 58 | 2013 |
The impact of bank competition and concentration on industrial growth G Liu, A Mirzaei, S Vandoros Economics Letters 124 (1), 60-63, 2014 | 46 | 2014 |
Competition in prescription drug markets: is parallel trade the answer? P Kanavos, S Vandoros Managerial and decision economics 31 (5), 325-338, 2010 | 41 | 2010 |
Raising the bar for market authorisation of new drugs H Naci, J Cylus, S Vandoros, A Sato, K Perampaladas Bmj 345, 2012 | 38 | 2012 |
Household expenditures for medicines and the role of free medicines in the Brazilian public health system AD Bertoldi, AJD Barros, AL Camargo, PC Hallal, S Vandoros, A Wagner, ... American journal of public health 101 (5), 916-921, 2011 | 38 | 2011 |
Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP P Kanavos, S Vandoros, P Garcia-Gonzalez Globalization and health 5, 1-13, 2009 | 38 | 2009 |
Greasy roads: the impact of bad financial news on road traffic accidents S Vandoros, G Kavetsos, P Dolan Risk analysis 34 (3), 556-566, 2014 | 35 | 2014 |
Economic uncertainty and suicide in the United States S Vandoros, I Kawachi European journal of epidemiology 36 (6), 641-647, 2021 | 33 | 2021 |
Introduction and utilization of high priced HCV medicines across Europe; implications for the future W De Bruijn, C Ibanez, P Frisk, H Bak Pedersen, A Alkan, ... Frontiers in pharmacology 7, 197, 2016 | 32 | 2016 |